Panelists discuss how bacterial infections, environmental triggers, and microbiome imbalances cause bronchiectasis ...

Discover how HSK31858 could transform bronchiectasis treatment by reducing flare-ups - read more about the latest trial ...

Researchers have discovered in a new study that treating airway inflammation with the experimental drug brensocatib lowers ...

No reduction in gepotidacin susceptibility following treatment was identified. 68% of the gepotidacin group had at least one drug-related adverse event, but most were mild-to-moderate and ...

Results of a large, global clinical trial spanning five continents with over 1,700 patients with bronchiectasis, published ...

Results of a large clinical trial demonstrated the benefits of an investigational, once-a-day pill called brenso­catib as a ...

For further information, please contact Professor Dr Felix Ringshausen, [email protected], telephone (0511) 532-3595. The original paper ‘Phase 3 Trial of the DPP1 Inhibitor Brensocatib ...

Environmental and Occupational Exposure: Chronic inhalation of inorganic and organic particulates, such as silica, asbestos, ...

Results of a large, global clinical trial spanning five continents with over 1,700 patients with bronchiectasis has demonstrated benefits of an investigational, once-a-day pill called brenso catib as ...

Verona continues to enroll subjects in a Phase 2 trial to assess the efficacy and safety of nebulized ensifentrine for the ...

A new phase 3 trial shows that DPP-1 inhibition with brensocatib reduces exacerbations and slows lung function decline in ...

A total of 1,680 adults and 41 adolescents were randomly assigned to brensocatib or placebo. The researchers found that the annualized rate of pulmonary exacerbations was 1.02, 1.04, and 1.29 in ...